Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.
Andrew Satlin, MD
A Phase 2 Clinical Trial to Study the Effect of TPN-101, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with Alzheimer's Disease
A GuideStar-Rated Charity
© Copyright 2025. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).